A case report in 2022 described a 77-year-old man with diagnosis of metastatic differentiated thyroid cancer and evidence of presence of mutation of BRAF K601E on liquid biopsy was treated with sorafenib, showing a good response to the treatment.[8]. Here, BRAF is linked to thyroid cancer.